10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
10.79
-0.02 (-0.19%)
At close: Jun 23, 2025, 4:00 PM
11.07
+0.28 (2.59%)
Pre-market: Jun 24, 2025, 6:12 AM EDT
10x Genomics Stock Forecast
Stock Price Forecast
The 15 analysts that cover 10x Genomics stock have a consensus rating of "Buy" and an average price target of $15.81, which forecasts a 46.52% increase in the stock price over the next year. The lowest target is $6.5 and the highest is $25.
Price Target: $15.81 (+46.52%)
Analyst Consensus: Buy
* Price targets were last updated on May 19, 2025.
Analyst Ratings
The average analyst rating for 10x Genomics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 7 | 8 | 8 | 8 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 16 | 16 | 16 | 16 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $26 → $18 | Buy | Maintains | $26 → $18 | +66.82% | May 19, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $14 | Buy | Reiterates | $14 | +29.75% | May 15, 2025 |
| UBS | UBS | Hold Maintains $14 → $12 | Hold | Maintains | $14 → $12 | +11.21% | May 13, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $7.5 → $6.5 | Strong Sell | Maintains | $7.5 → $6.5 | -39.76% | May 12, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $18 → $15 | Strong Buy | Maintains | $18 → $15 | +39.02% | May 12, 2025 |
Financial Forecast
Revenue This Year
595.41M
from 610.79M
Decreased by -2.52%
Revenue Next Year
631.51M
from 595.41M
Increased by 6.06%
EPS This Year
-1.22
from -1.52
EPS Next Year
-0.94
from -1.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 640.5M | 703.8M | 805.7M | ||
| Avg | 595.4M | 631.5M | 687.7M | ||
| Low | 560.2M | 569.4M | 614.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.9% | 18.2% | 27.6% | ||
| Avg | -2.5% | 6.1% | 8.9% | ||
| Low | -8.3% | -4.4% | -2.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.03 | -0.46 | -0.02 | ||
| Avg | -1.22 | -0.94 | -0.69 | ||
| Low | -1.48 | -1.23 | -1.11 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.